Need professional-grade analysis? Visit stockanalysis.com
$16.76M
N/A
N/A
N/A
OUTLOOK THERAPEUTICS INC (OTLK) trades on United States in USD. The company is classified in the Healthcare sector under the Biological Products industry. The stock currently trades at $0.29, down 9.14% from the previous close.
Over the past year, OTLK has traded between a low of $0.20 and a high of $2.97. The stock has lost 81.3% over this period. It is currently 90.2% below its 52-week high.
OUTLOOK THERAPEUTICS INC has a market capitalization of $16.76M.
Outlook Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic bevacizumab product formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration agreements with Cencora. Outlook Therapeutics, Inc. was formerly known as Oncobiologics, Inc. and changed its name to Outlook Therapeutics, Inc. in November 2018. Outlook Therapeutics, Inc. was incorporated in 2010 and is based in Iselin, New Jersey.
Side-by-side comparison against top Healthcare peers.